AE1            Adverse Event
AE2            Adverse Event (Action Taken)
BP1            Bone Marrow Aspirate and Biopsy
BP2            Bone Marrow Aspirate and Biopsy (Continued)
CANCTX         Subsequent Antineoplastic Therapy
CH             DLBCL Disease History
CM             Concomitant Medications / Products
CMPS           Prior DLBCL Surgery
CMRAD          Prior DLBCL Radiation
CMRX1          Prior DLBCL Therapy Prompt
CMRX2          Prior DLBCL Therapy
CMRX3          Prior DLBCL Therapy (Continued)
CT             Imaging by CT/MRI
DEATH          Death
DISCBTK        Study Drug Discontinuation-Ibrutinib
DISCEPOC       Study Drug Discontinuation-EPOCH-R
DM             Demographics
DSEOT          Follow-Up Visit Prompt
DSEXIT         Study Exit
ECHO           ECHOCARDIOGRAM / MUGA
ECOG           ECOG
EG1            Electrocardiogram - Assessment
EG2            Electrocardiogram - Triple Measurements
EXBTK          Ibrutinib Dose Administration
EXCYC          Cyclophosphamide Dose Administration
EXDOX          Doxorubicin Dose Administration
EXETO          Etoposide Dose Administration
EXLEN          Lenalidomide Dose Administration
EXPEG          Pegfilgrastim Dose Administration
EXPRED         Prednisone Dose Administration
EXRIT          Rituximab Dose Administration
EXVIN          Vincristine Dose Administration
IE             Informed Consent
LBBIO          Biomarker Sample (Central Lab)
LBCHEML1       Serum Chemistry (Local Lab)
LBCHEML2       Serum Chemistry (Local Lab) (Continued)
LBCOAGL        Coagulation Studies (Local Lab)
LBCREATL       Creatinine Clearance (Local Lab)
LBHEML1        Serum Hematology (Local Lab)
LBHEML2        Serum Hematology (Local Lab) (Continued)
LBHEP          Hepatitis Serologies (Local Lab)
LBHEPA         Hepatitis Serologies (Amendment)
LBPREGL        Pregnancy Test
LBTB           Tumor Biopsy for Eligibility
LBTSHL         Thyroid Stimulating Hormones (Local Lab)
LBURINE        Urinalysis (Local Lab)
MH             Medical History
ML             Other Malignancy
NE1            Extranodal Non-Target Lesion Assessment
NE2            Extranodal Non-Target Lesion Assessment Comment
NN1            Nodal Non-Target Lesion Assessment
NN2            Nodal Non-Target Lesion Assessment Comment
PE1            Physical Exam at Baseline
PE2            Physical Exam at Baseline (Continued)
PE3            Physical Exam at Post-Baseline
PK             Pharmacokinetics (PK)
PT1            Imaging by PET
PT2            Imaging by PET (Individual Sites)
RECONS         Subject Re-Consent
RFSTDTC        Reference Start Date
RS1            Response Evaluation
RS2            Response Evaluation (Mode of Progression)
SCHED          Scheduled Study Visit Prompt
STAGING        Staging
SURVIVAL       Survival Status
TB             Optional Tumor Biopsy Sample
TL1            Target Lesion Assessment
TL2            Target Lesion Assessment Comment
VS             Vital Signs